Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the FDA.
The recall affects batch BF21002895 of Mylan’s unbranded insulin glargine-yfgn, a long-acting insulin analog indicated for improving glycemic control for adults and children with type 1 diabetes and adults with type 2 diabetes. People receiving treatment with more than one type of insulin may mix up insulin products if there is a missing label on the pens. This could result in less optimal